MFN Drug Pricing: Beyond Lower Drug Prices
The debate around MFN pricing has largely focused on one question: Will American patients pay less for medicines?
But a more important question may be emerging: What happens to the global pharmaceutical system if MFN succeeds?
Let's recap!
Most-Favoured-Nation (MFN) drug pricing is a U.S. policy that requires Medicare to pay no more for a drug than the lowest price available in comparable developed nations. American patients pay 2-3x more for the same medicines than patients in Germany, the UK, or Canada, not because the drugs are different but because those governments negotiate significantly lower prices with pharmaceutical manufacturers. The U.S. represents less than 5% of the world's population yet contributes a disproportionate share of global pharmaceutical profits.
A series of manufacturer agreements have begun moving MFN from policy discussion to commercial reality, influencing pricing decisions, investment commitments and broader corporate strategy. The policy has begun to reshape how pharmaceutical companies price drugs, where they invest capital, and how they sequence global launches.
This explores the underlying economics of the trade off and asks the question that will define the next decade of pharmaceutical strategy: can you compress the world's most profitable drug market without reducing what the world ultimately invests in new medicines?
What has changed since MFN?
The GLP-1 Moment
The clearest signal MFN had practical implications became visible through the most commercially significant therapeutic category of the decade: GLP-1 therapies for obesity and diabetes.
In late 2025, under the TrumpRx direct to consumer purchasing channel, a government backed platform designed to bypass traditional intermediaries announced monthly prices for leading GLP-1 therapies:
- Ozempic and Wegovy: from approximately $1,000–$1,350 per month to roughly $350
- Zepbound (tirzepatide): projected at approximately $346 per month through direct channels
- Future oral GLP-1 therapies: indicative pricing near $150 per month at launch
These are not marginal adjustments. They represent price reductions of 60–75% relative to prevailing U.S. list prices and they arrived in a category where annual U.S. spending was already measured in the tens of billions of dollars.
Manufacturer Agreements
The GLP-1 numbers were the most visible output, but the broader agreements covered several consistent commitments
- Expanded Medicaid access with MFN benchmarked pricing for selected high spend therapies
- Direct-to-patient purchasing channels offering medicines at reduced prices
- Application of MFN pricing principles to future innovative therapies entering the U.S. market
- Commitments to reinvest incremental revenues and manufacturing capacity into the U.S. ecosystem
The agreements were not uniform, nor were they voluntary. The context of Section 232 pharmaceutical tariffs provided strong incentive for manufacturers to negotiate rather than resist.
Economic Trade off
The administration's core assumption is that lower U.S. pricing can be offset through upward pressure on international prices, effectively redistributing the global revenue base rather than shrinking it.
International pricing is not a free variable. Reimbursement decisions in markets like Germany (AMNOG), the UK (NICE), and France (HAS) are governed by statutory health technology assessment frameworks where value thresholds, clinical evidence requirements, and political sensitivity around public healthcare budgets create structural ceilings on what manufacturers can achieve. Requesting significantly higher prices in these markets risks delayed reimbursement, restricted access or rejection.
If the international offset is smaller than the projected, the MFN framework creates net revenue compression across the pharmaceutical industry, with consequences for capital allocation toward future R&D.
Economic literature on pharmaceutical innovation has consistently suggested that expected returns play an important role in determining R&D investment, particularly in high-risk therapeutic areas such as CNS, rare diseases and next generation oncology.
Three Strategic Responses
Faced with this trade off, manufacturers have adopted a consistent three part strategic response:
Channel Containment
Manufacturers have concentrated pricing concessions within Medicaid and direct-purchase channels, preserving commercial insurance economics which represents most of the branded drug spending as much as possible. This is a controlled compromise: accept visible pricing reductions in high-scrutiny segments to protect the broader commercial base.
Trading pricing concessions for tariff stability
For several major manufacturers, the strategic calculation was not primarily about drug pricing, it was about supply chain stability. Section 232 tariff exposure posed a significant risk to globally integrated manufacturing networks dependent on imported active pharmaceutical ingredients and finished dose forms.
“We now have the certainty and stability we need on two critical fronts - tariffs and pricing.”
From an industry perspective, this may have been viewed as a manageable pricing concession in exchange for avoiding significantly broader supply chain disruption. In economic terms, it was a rational hedge: accept a bounded, visible cost today to avoid an unbounded, unpredictable one tomorrow
Accelerating U.S. manufacturing commitments
A striking feature of the manufacturer agreements was the scale of announced U.S. manufacturing and R&D investment commitments:
These pledges serve several purposes simultaneously like supply chain resilience, alignment with industrial policy objectives, improved tariff insulation and political positioning.
The European Ripple Effect
MFN pricing introduces a profound strategic challenge for European pharmaceutical markets.
Under international reference pricing dynamics, launching a product first in lower priced European markets can indirectly constrain future pricing potential in the United States. As a result, companies may increasingly delay European launches, prioritize the U.S. market or avoid certain lower-priced markets altogether.
Europe's ecosystem already operates under compounding structural disadvantages like limited late stage funding, shallower capital markets, slower HTA pathways and persistent domestic pricing pressure. For years, strong U.S. profitability helped offset many of these structural weaknesses.
Novartis CEO, Vas Narasimhan recently warned that increasingly aggressive pricing reforms in Europe could undermine the region's attractiveness for pharmaceutical innovation, research and manufacturing investment.
Europe risks evolving into primarily a commercial market for medicines developed elsewhere rather than remaining a leading global hub for pharmaceutical innovation.
Conclusion
MFN at its core is a redistribution argument that the U.S. has been subsidising the world's drug costs for long enough and that a more equitable spread of the global pricing burden is overdue. That argument has political merit but the economic consequences do not follow as neatly. Compressing the most profitable market in the global pharmaceutical system does not simply reduce industry margins it alters where capital flows and how the global launch sequence gets ordered. The manufacturers who signed agreements in 2025 understood this, which is why the real negotiation was never only about drug prices. It was about tariff exposure, supply chain continuity, and industrial policy positioning.
What success would look like is harder to define than the policy itself. A version of MFN that holds prices down without hollowing out the pipeline would require a global framework where innovation costs are shared more equitably across markets rather than simply transferred away from the one willing to pay. That is a much more complex problem to solve.
The question MFN ultimately poses is not whether American patients deserve lower prices, they do. It is whether price compression alone constitutes a healthcare system strategy or whether it is a political solution to an economic problem that runs considerably deeper. If the world's largest pharmaceutical profit pool becomes structurally constrained, who funds the next generation of medical innovation and on whose terms?
References:
- The White House. Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients (Executive Order). The White House, May 2025. whitehouse.gov
- The White House. Savings from Most-Favored-Nation Drug Pricing Policy. The White House, May 2026. whitehouse.gov
- The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients — Eli Lilly ($27B) and Novo Nordisk ($10B) U.S. manufacturing investment commitments. The White House, Nov 2025. whitehouse.gov
- Pfizer Inc. Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients. Pfizer Press Release, Sep 2025. pfizer.com
- Roth, C. Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'. CNBC, Apr 2026. cnbc.com
Prepared by PharmSight Research & Analytics for informational purposes only. Pricing, policy and investment figures are drawn from published government and company disclosures, and should not be construed as medical or investment advice.